Abstract
ABSTRACT Background: Worldwide, ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death. Most of the ovarian cancers have spread beyond the ovary by the time of diagnosis; they account for a disproportionate number of deaths from cancer of the female genital tract. Ki-67 is one of the prognostic markers which determine the growth fraction of a tumor, and its overexpression is associated with malignancy, tumor aggression, prognosis, and metastasis. Overexpression of HER2/neu is most commonly observed in the breast, gastric carcinoma, lungs, and ovaries. Material and Methods: The study is conducted at the central diagnostic laboratory of the Pathology department at A.J. Institute of Medical Sciences and Research Centre, Mangalore. This was a 24 months prospective study. Hematoxylin and eosin sections were studied, and Ki-67 and HER2/neu immunohistochemistry was done. Results: A total of 61 cases were studied. Serous carcinoma (31%) was the most common type of tumor found in our study. The current study shows significant association between nature of tumor and KI 67 with Chi square value = 52.820 with P < 0.001. There was no significant association between the grade of differentiation and Ki-67 index, with P = 0.78. The association between the tumor staging and Ki-67 did not show any significance, with Chi-square = 21.574 and P value = .272. HER2/neu did not show any association with tumor grade, size, staging, and other variables. 100% of cases were tested negative in this study. Conclusion: High Ki-67 expression was associated with a malignant group of tumors. HER2/neu did not show any association in the current study as 100% cases were negative. Further investigation of HER2/neu with ISH method is necessary to rule out false negative results.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call